Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity (Q39028302)

8 September 2017

title

Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity (English)

1 reference

8 September 2017

0 references

Chen-Yi Chiang

1 reference

8 September 2017

Chun-Hsiang Hsieh

1 reference

8 September 2017

Mei-Yu Chen

1 reference

8 September 2017

Jy-Ping Tsai

1 reference

8 September 2017

Hsueh-Hung Liu

1 reference

8 September 2017

Shih-Jen Liu

1 reference

8 September 2017

Pele Chong

1 reference

8 September 2017

Chih-Hsiang Leng

1 reference

8 September 2017

Hsin-Wei Chen

1 reference

8 September 2017

language of work or name

English

0 references

publication date

30 January 2014

1 reference

8 September 2017

1 reference

8 September 2017

1 reference

8 September 2017

1 reference

8 September 2017

page(s)

1346-1353

1 reference

Dengue: a continuing global threat

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Refining the global spatial limits of dengue virus transmission by evidence-based consensus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

The global distribution and burden of dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Dengue vaccines: progress and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Development of dengue DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Domain III of the envelope protein as a dengue vaccine target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

A Novel Single-Dose Dengue Subunit Vaccine Induces Memory Immune Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Characterization of Antibody Responses to Combinations of a Dengue Virus Type 2 DNA Vaccine and Two Dengue Virus Type 2 Protein Vaccines in Rhesus Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Antigen-specific memory B cell development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

The demand for a dengue vaccine: a contingent valuation survey in Metro Manila

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.041

10.1016/J.VACCINE.2014.01.041

7 January 2021

Identifiers

DOI

1 reference

8 September 2017

1 reference